Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences industry. In today's Pharmaceutical Executive Daily, an FDA advisory panel narrowly votes to recommend easing restrictions on four unapproved peptides, a supply chain expert discusses how China's export controls are exposing vulnerabilities in the U.S. pharmaceutical supply chain, and a pharmacy benefits executive lays out a business case for more targeted employer-based GLP-1 coverage. The votes don't constitute FDA approval and came over the objections of agency scientists, who said there isn't enough evidence to assess the compounds' safety and effectiveness. He says the resulting risks, including licensing delays and operational restrictions, make clear escalation protocols and diversified supplier bases essential for manufacturers. Thanks for listening to Pharmaceutical Executive Daily.